Alternative Cancer Treatment Enlists the Body’s Inner Physician
Using the Immune System to Pursue a Cure
Although “Awakening the Physician Within” may seem like a good title for a New York Times best seller, it is the most concise explanation at the heart of clinical biomedical cancer research conducted by Dr. Thomas E. Wagner, Ph.D. The cofounder of Perseus PCI, Wagner is a world-renowned biomedical scientist, innovator and entrepreneur who has pioneered some of the past half-century’s most significant biomedical technologies used today in the study and elimination of cancer. His cancer center, Perseus PCI, provides an alternative cancer treatment for people suffering with all stages of solid tumor cancer.
Wagner’s breakthrough technology focuses on targeted immunotherapy that uses an individual’s dendritic cells, a type of immune cell collected by drawing blood from the patient, and the cells from the patient’s tumor, which are obtained at the time of biopsy to create a vaccine. Personalized treatment uses the uniqueness of the individual’s tumor antigenic profile in order to stimulate the production of antibodies, which are the weapons of the body’s elite attack force.
“Since 1963, science has learned more about the human body and how it works than any other period in the entire history of our world. For example, we know the complete sequence of the human genome, which means we have identified the sequence of chemical base pairs, that make up human DNA as well as what sequence has to take place to cause cancer. Our genes did not come into being for the purpose of mutating and causing cancer; their purpose is to regulate homeostasis, a dynamic process, which is constantly adjusting our body’s internal physiological processes to maintain the stability of our health. In other words, we’ve had a vast increase in knowledge that tells us how life works from the tiniest molecules to tissues to organs and systems, so we shouldn’t be treating cancer the same way we did 50 years ago,” explains Wagner whose research has resulted in a reasonable and logical approach to cancer that stimulates the incredibly powerful immune system.
Wagner advises that no one will ever be able to develop anything with a potential to cure disease that even comes close to our immune system. “This is why immunotherapy-based Dendritic Cell Tumor Vaccine enlists the intelligence of the immune system’s dendritic cells and introduces them to entire cell population of the tumor. They educate themselves on how to wake up the natural killer cells to the presence of the ‘stealth’ tumor, which they then attack and destroy,” explains Wagner.
Immunotherapy-based Dendritic Cell Tumor Vaccine, a substitute for chemotherapy and radiation, is easily administered by injection under the skin once a month for four months. A patient’s quality of life is either improved or maintained during the treatment process. The safety and effectiveness of this technology has been proven in U.S. FDA sanctioned trials. While the U.S. approval process is ongoing, the Health Practice Commission of the Cayman Islands has approved this treatment for manufacture and administration as a special category of clinical trials.
The initial patient consultation takes place in Greenville, South Carolina, and the vaccine is administered after a screening process, which includes a mandatory confirmation of the patient’s ability to have at least one milligram of tumor tissue removed and frozen. Once this portion of the tumor is removed, the tumor specimen is processed at the Perseus Cayman Healthcare facility in Georgetown, Grand Cayman, where the patient’s blood is drawn and the vaccine process started. The vaccine is completed within 48 hours, and on the morning of third day, the patient receives the first vaccine by subcutaneous injection. The patient, who is able to return home later in the afternoon, returns to Grand Cayman once a month for the following three months to have the full series of four vaccines administered.
The dendritic cell-based immunotherapy has already been shown to be effective against melanoma, renal cell carcinoma and neuroblastoma tumors in clinical trials conducted in the United States.
For more information, visit PerseusPCI.com or call 888-979-7402.
Linda Sechrist is the senior staff writer for Natural Awakenings. Visit her website ItsAllAboutWe.com for recorded interviews.Edit ModuleShow Tags